8.52
price down icon1.05%   -0.09
after-market 시간 외 거래: 8.56 0.04 +0.47%
loading
전일 마감가:
$8.61
열려 있는:
$8.63
하루 거래량:
3.32M
Relative Volume:
0.75
시가총액:
$1.78B
수익:
$503.49M
순이익/손실:
$-53.47M
주가수익비율:
-32.77
EPS:
-0.26
순현금흐름:
$-26.89M
1주 성능:
-4.91%
1개월 성능:
-15.64%
6개월 성능:
+11.96%
1년 성능:
+19.33%
1일 변동 폭
Value
$8.495
$8.745
1주일 범위
Value
$8.445
$9.05
52주 변동 폭
Value
$6.015
$11.31

바이오크리스트 Stock (BCRX) Company Profile

Name
명칭
Biocryst Pharmaceuticals Inc
Name
전화
919-859-1302
Name
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
직원
580
Name
트위터
@biocrystpharma
Name
다음 수익 날짜
2025-02-24
Name
최신 SEC 제출 서류
Name
BCRX's Discussions on Twitter

BCRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
8.52 1.87B 503.49M -53.47M -26.89M -0.26
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
147.37 69.30B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.44 47.50B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.53 44.47B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.31 18.83B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
293.12 13.43B 2.99B 1.21B 1.13B 25.06

바이오크리스트 Stock (BCRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-29 개시 Cantor Fitzgerald Overweight
2025-02-25 개시 Wedbush Outperform
2023-11-20 재개 JP Morgan Overweight
2023-09-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2023-08-04 업그레이드 Jefferies Hold → Buy
2023-07-13 업그레이드 BofA Securities Neutral → Buy
2023-02-22 업그레이드 Needham Hold → Buy
2022-11-02 업그레이드 Evercore ISI In-line → Outperform
2022-08-05 다운그레이드 Evercore ISI Outperform → In-line
2022-08-05 다운그레이드 Oppenheimer Outperform → Perform
2022-04-18 다운그레이드 Barclays Overweight → Equal Weight
2022-04-11 다운그레이드 BofA Securities Buy → Neutral
2021-12-10 개시 Oppenheimer Outperform
2021-08-06 다운그레이드 Jefferies Buy → Hold
2021-08-03 개시 Cantor Fitzgerald Overweight
2021-03-01 개시 Cowen Outperform
2020-09-29 재개 JP Morgan Overweight
2020-06-17 개시 BTIG Research Neutral
2020-05-05 업그레이드 Barclays Equal Weight → Overweight
2019-11-15 업그레이드 BofA/Merrill Neutral → Buy
2019-05-24 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2018-11-16 재개 Piper Jaffray Overweight
2018-08-08 재개 JP Morgan Overweight
2018-07-17 업그레이드 BofA/Merrill Underperform → Neutral
2018-06-22 개시 Seaport Global Securities Neutral
2018-01-02 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2017-12-20 개시 Barclays Equal Weight
2017-09-15 개시 RBC Capital Mkts Sector Perform
2017-09-06 업그레이드 JP Morgan Neutral → Overweight
2017-09-06 업그레이드 Jefferies Hold → Buy
2017-02-16 개시 Ladenburg Thalmann Buy
2016-08-12 업그레이드 Piper Jaffray Neutral → Overweight
2016-08-04 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 재확인 FBR Capital Outperform
2016-02-09 다운그레이드 JP Morgan Overweight → Neutral
2016-02-09 다운그레이드 Needham Buy → Hold
모두보기

바이오크리스트 주식(BCRX)의 최신 뉴스

pulisher
02:45 AM

What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional

02:45 AM
pulisher
10:53 AM

BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha

10:53 AM
pulisher
07:13 AM

BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Quiver Quantitative

07:13 AM
pulisher
07:06 AM

BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewswire

07:06 AM
pulisher
Jul 20, 2025

BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Management Insights - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What drives BioCryst Pharmaceuticals Inc. stock priceFree Capital Efficiency Planning - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

How To Trade (BCRX) - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 18, 2025

BioCryst appoints Babar Ghias as CFO - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsCarefully Curated High Return Stocks - beatles.ru

Jul 18, 2025
pulisher
Jul 18, 2025

Is BioCryst Pharmaceuticals Inc. a good long term investmentOutstanding stock performance - Jammu Links News

Jul 18, 2025
pulisher
Jul 15, 2025

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 14, 2025

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB - The Globe and Mail

Jul 14, 2025
pulisher
Jul 13, 2025

RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN

Jul 13, 2025
pulisher
Jul 10, 2025

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 - Stock Titan

Jul 09, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals acquires BioCryst’s Galidesivir - grafa.com

Jul 08, 2025
pulisher
Jul 08, 2025

BioCryst Pharmaceuticals appoints Babar Ghias as CFO By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals Acquires Galidesivir Antiviral Program from BioCryst Pharmaceuticals - AInvest

Jul 08, 2025
pulisher
Jul 07, 2025

CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com

Jul 07, 2025
pulisher
Jul 07, 2025

Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech

Jul 07, 2025
pulisher
Jul 07, 2025

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - Yahoo

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals (BCRX) Appoints New CFO, Babar Ghias - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals appoints Babar Ghias as CFO - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals shares rise 1.37% after-hours following the appointment of Babar Ghias as CFO. - AInvest

Jul 07, 2025
pulisher
Jul 06, 2025

BioCryst Appoints Babar Ghias Chief Financial Officer and Head o - GuruFocus

Jul 06, 2025
pulisher
Jul 06, 2025

BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M - Insider Monkey

Jul 06, 2025
pulisher
Jul 05, 2025

10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey

Jul 05, 2025
pulisher
Jul 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 03, 2025
pulisher
Jul 03, 2025

BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan

Jul 03, 2025
pulisher
Jul 01, 2025

BioCryst Pharma (BCRX) Receives Boost with Increased Price Target | BCRX Stock News - GuruFocus

Jul 01, 2025
pulisher
Jun 30, 2025

BioCryst Pharma (BCRX) Maintains Outperform Rating and $13 Price Target | BCRX Stock News - GuruFocus

Jun 30, 2025
pulisher
Jun 30, 2025

BCRX Stock Rating and Price Target Update by Wedbush | BCRX Stoc - GuruFocus

Jun 30, 2025
pulisher
Jun 29, 2025

BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal - MedCity News

Jun 29, 2025
pulisher
Jun 28, 2025

BioCryst to sell European Orladeyo business for up to $264M - MSN

Jun 28, 2025
pulisher
Jun 27, 2025

BioCryst Pharmaceuticals (BCRX) Receives Reiterated Buy Rating from Needham | BCRX Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules - BioPharma Dive

Jun 27, 2025

바이오크리스트 (BCRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$71.56
price up icon 1.97%
$14.68
price down icon 0.68%
$8.90
price up icon 0.23%
drug_manufacturers_specialty_generic RDY
$14.55
price up icon 0.48%
$131.83
price down icon 0.14%
$293.12
price up icon 0.38%
자본화:     |  볼륨(24시간):